(Q33399928)

English

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

systemic therapy

1 reference

based on heuristic

inferred from title

Gedske Daugaard

object named as

Gedske Daugaard

6

0 references

author name string

Joaquim Bellmunt

1

1 reference

Europe PubMed Central

26 July 2017

Hans von der Maase

2

1 reference

Europe PubMed Central

26 July 2017

Graham M Mead

3

1 reference

Europe PubMed Central

26 July 2017

Iwona Skoneczna

4

1 reference

Europe PubMed Central

26 July 2017

Maria De Santis

5

1 reference

Europe PubMed Central

26 July 2017

Andreas Boehle

7

1 reference

Europe PubMed Central

26 July 2017

Christine Chevreau

8

1 reference

Europe PubMed Central

26 July 2017

Luis Paz-Ares

9

1 reference

Europe PubMed Central

26 July 2017

Leslie R Laufman

10

1 reference

Europe PubMed Central

26 July 2017

Eric Winquist

11

1 reference

Europe PubMed Central

26 July 2017

Derek Raghavan

12

1 reference

Europe PubMed Central

26 July 2017

Sandrine Marreaud

13

1 reference

Europe PubMed Central

26 July 2017

Sandra Collette

14

1 reference

Europe PubMed Central

26 July 2017

Richard Sylvester

15

1 reference

Europe PubMed Central

26 July 2017

Ronald de Wit

16

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

27 February 2012

1 reference

Europe PubMed Central

26 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

26 July 2017

30

1 reference

Europe PubMed Central

26 July 2017

1107-1113

1 reference

Europe PubMed Central

26 July 2017

10

1 reference

Europe PubMed Central

26 July 2017

RECIST revisited: a review of validation studies on tumour assessment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Spreading of embryologically distinct urothelial cells is inhibited by SPARC

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Normal and abnormal development of the urogenital tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

21 June 2018

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

31 October 2018

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

31 October 2018

Distinct patterns of microsatellite instability are seen in tumours of the urinary tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341152

31 October 2018

Urothelial umbrella cells of human ureter are heterogeneous with respect to their uroplakin composition: different degrees of urothelial maturity in ureter and bladder?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22370319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22370319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequent microsatellite instability in sporadic tumors of the upper urinary tract

1 reference

https://pubmed.ncbi.nlm.nih.gov/22370319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22370319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22370319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22370319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2011.38.6979

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33399928&oldid=1953361242"